93Z.F MARINOMED BIOTECH AG INH.

Healthcare Biotechnology Frankfurt Exchange
3.76 EUR
Close of Nov 11, 2026
3.00 20.00
Market cap
EUR 7.52M
P/E
0.4x
P/B
605.08x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 93Z.F undervalued?

Graham number

The Graham number of MARINOMED BIOTECH AG INH. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MARINOMED BIOTECH AG INH. fundamental analysis

No fundamental analysis for MARINOMED BIOTECH AG INH. yet.

MARINOMED BIOTECH AG INH. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MARINOMED BIOTECH AG INH.

Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation developmen…

Full company profile